ArticleEClinicalMedicine2022

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.

Xin-Xin Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.